Gilead Sciences to Acquire MiroBio

Gilead Sciences, Inc. and MiroBio, a privately-held UK-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash.